Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Abstract   The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the highe...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2022-09, Vol.226 (4), p.673-677
Main Authors: Streng, Bianca M M, Bont, Marin, Delemarre, Eveline M, Binnendijk, Rob S, Smit, Gaby, den Hartog, Gerco, Coppus, Antonia M W, de Vries, Esther, Weijerman, Michel E, Lamberts, Regina, de Graaf, Gert, van der Klis, Fiona R, Vidarsson, Gestur, Rave, Neele, Bont, Louis J, Wildenbeest, Joanne G
Format: Article
Language:English
Subjects:
Antibody response
Brief Report
Clinical trials
Coronaviruses
Down's syndrome
Editor's Choice
mRNA
Severe acute respiratory syndrome coronavirus 2
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract   The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1–specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]–1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. Clinical Trials Registration NCT05145348. In this prospective cohort study that included 222 adults with Down syndrome, a significantly lower antibody response was found after SARS-CoV-2 mRNA or vector vaccination compared to healthy controls. After mRNA vaccination, lower antibodies were found with increasing age.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiac235